• DISCOVERY
    comes
    from
    within.

    Link alterations to the underlying biology of cancer with unparalleled specificity.

  • ACCURACY
    comes
    from
    within.

    Accurate genomic technologies tailored to solve fundamental challenges in oncology.

  • HOPE
    comes
    from
    within.

    Unlocking actionable information to inform treatment decisions.

  • ACCESS
    comes
    from
    within.

    Partnering to make our novel genomic technologies widely available to patients.

  • SOLUTIONS
    come
    from
    within.

    Offering a portfolio of regulated genomic products for laboratories worldwide.

Innovative genomic solutions

to unlock actionable
information from the genome.

Advanced cancer genome analysis to help researchers identify elusive cancer-related genetic changes.

» View our full suite

Obtain the unique genetic information about an individual tumor and make informed treatment decisions.

» Learn about MYPG

Build high-quality in-house with comprehensive NGS testing and analysis of tissue and plasma.

» See Our Diagnostic Solutions

PHARMA-BIOTECH COMPANIES

Advanced cancer genome analysis to help researchers identify elusive cancer-related genetic changes.

PATIENTS & PHYSICIANS

Obtain unique genetic information about individual tumors and make informed treatment decisions.

MOLECULAR LABORATORIES

Build high-quality in-house with comprehensive NGS testing and analysis of tissue and plasma.

recently posted

Circulating tumor DNA

PGDx’s advisor Bert Volgelstein spoke at AACR’s Opening Plenary about the Road to Cancer Cures- Discover, Predict, Prevent, and Treat. Listen now:

latest news & press releases

Personal Genome Diagnostics’ Expanded PlasmaSELECT™ 64 Is First Liquid Biopsy Pan-Cancer Profiling Panel to Include MSI Analyses for Immuno-Oncology

—First Liquid Biopsy Assay to Include Assessment of Microsatellite Instability Status (MSI), a Surrogate Marker for High Tumor Mutational Load, that Helps Identify Patients Most Likely to Benefit from Treatment with Immuno-Oncology Therapies such as Checkpoint Inhibitors— —Accurately Identifies Clinically... » View

PGDx Details Design of Small-Panel Mutational Burden Test; Plans IVD Development

NEW YORK (GenomeWeb) – Personal Genome Diagnostics announced earlier this month that it is developing a non-invasive next-gen sequencing assay to help identify which cancer patients have the best chance at responding to treatment with immune checkpoint inhibitors.The company received... » View

Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer

 » View

Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors

AbstractInflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer that remains poorly understood at the molecular level. Comprehensive tumor profiling was performed to understand clinically actionable alterations in IBC. Targeted next-generation sequencing (NGS) and IHC were... » View

Latest Publication

Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer

Available on CancerDiscovery

Immune checkpoint inhibitors have shown significant therapeutic responses against tumors containing increased mutation-associated neoantigen load. We have examined the evolving landscape of tumor neoantigens during the emergence of acquired resistance in non-small cell lung cancer patients after initial response to immune checkpoint blockade with anti-PD1 or anti-PD-1/anti-CTLA4 antibodies.

Industry News

New genomic analysis technology has been used to demonstrate how cancer drug resistance evolves

Available on SelectScience

Mark Sausen, PGDx Vice President of Research & Development, commented, "Despite the increased efficacy and durability of treatment seen with IO therapies, some patients develop resistance to the therapy, and this study for the first time elucidates how this may result from the evolving cancer genome landscape..."

latest news & press releases

Personal Genome Diagnostics’ Expanded PlasmaSELECT™ 64 Is First Liquid Biopsy Pan-Cancer Profiling Panel to Include MSI Analyses for Immuno-Oncology

—First Liquid Biopsy Assay to Include Assessment of Microsatellite Instability Status (MSI), a Surrogate Marker for High Tumor Mutational Load, that Helps Identify Patients Most Likely to Benefit from Treatment with Immuno-Oncology Therapies such as Checkpoint Inhibitors— —Accurately Identifies Clinically... » View

PGDx Details Design of Small-Panel Mutational Burden Test; Plans IVD Development

NEW YORK (GenomeWeb) – Personal Genome Diagnostics announced earlier this month that it is developing a non-invasive next-gen sequencing assay to help identify which cancer patients have the best chance at responding to treatment with immune checkpoint inhibitors.The company received... » View

Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer

 » View

Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors

AbstractInflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer that remains poorly understood at the molecular level. Comprehensive tumor profiling was performed to understand clinically actionable alterations in IBC. Targeted next-generation sequencing (NGS) and IHC were... » View